Hansoh Pharmaceutical (03692.HK) Announces NMPA Approval of Pegmolesatide Injection (Shenglai®), a Novel Long-Acting ESA for Anemia in Chronic Kidney Disease

Intelligent Finance APP, HANSOH PHARMA (03692) announced that "Pegmotercept Injection" (brand name "Saint Laurent"), a Class 1 innovative drug independently developed by its subsidiary Jiangsu Hansoh Pharmaceutical Group Co., Ltd.^®"") has been granted a drug registration certificate by the National Medical Products Administration of China.

Saint Laurent^®It is a long-acting peptide erythropoiesis-stimulating agent (ESA) that promotes red blood cell proliferation in the body. It is suitable for treating anemia caused by chronic kidney disease (CKD), including adult non-dialysis patients who have not received ESA treatment and adult dialysis patients receiving short-acting erythropoietin therapy.

In addition, Saint Laurent^®The acquisition of the drug registration certificate will further enrich and improve the group's product portfolio.